Quad introduces MagCloudz Streptavidin Cell Separation Kit to redefine translational medical research

Innovative MagCloudz™ Streptavidin Cell Separation Kit to enable breakthroughs in translational medicine and cell therapy via simple, cell-friendly capture and release technology

The most promising areas of translational medical research, including CAR-T cancer therapies and stem cell-based regenerative medicine, require the isolation and purification of large numbers of viable, functional cells. There is growing demand from researchers and clinicians for technologies that provide high viability, enhanced efficiency and scalability to optimize conventional cell separation techniques.

Quad Technologies Inc ("Quad"), developer of a novel cell separation technology, has secured a substantial amount of capital from its Series A round to accelerate development of disruptive cell processing technologies for translational medicine applications. The investment has enabled Quad to launch its MagCloudz™ Streptavidin Cell Separation Kit, which is the first commercially available product incorporating its proprietary QuickGel™ technology. The MagCloudz kits enable straightforward, scalable and fast cell separation with unique magnetic particle dissociation, resulting in complete label free cells for applications including T Cell purification, stem cell isolation, circulating tumor cell (CTC) separation and immunotherapy.

QuickGel is a unique dissolvable hydrogel technology that enables high efficiency purification and release of cells of interest. Delivering drastically improved cell viability, purity and recovery, QuickGel overcomes the limitations of other commercially available cell capture chemistries and enables researchers to simplify their cell separation and cell therapy workflows.

The company, backed by prominent investors including Keswick Ventures, is set to disrupt current cell separation and cell therapy workflows and this investment follows initial funding from investors in the Boston, MA and Houston, TX regions earlier this year.

Ian Ratcliffe from Keswick Ventures explained:

Immunotherapy, cell therapy and cell separation are significant growth areas within regenerative medicine and all face challenges around scalability. The availability of the MagCloudz kits will revolutionize the cell separation market and provide researchers with the speed, quality and adaptability they need. We are excited to be part of this next phase of growth and looking forward to working with the team at Quad to deliver this game-changing solution to market.

"Utilizing our groundbreaking QuickGel technology, our MagCloudz kits will truly disrupt existing cell separation and cell therapy research workflows to develop breakthrough therapies for the clinic and we are delighted to be the first to bring these benefits to market," explained Sean Kevlahan CEO, "We will continue to strengthen and build on our existing collaborations to solve the current challenges associated with cell separation and evolve our solutions to meet customer needs in high value applications."